Improving diagnostics

with help from alpacas

Tuberculosis is a global health crisis

10.6

million new cases of TB each year.

29%

of those cases will go undiagnosed.

half

of those with TB will lose over 20% of their household income to healthcare costs and lost wages

Our mission is to revolutionize TB diagnostics by developing effective and user-friendly solutions that are affordable and accessible, particularly for the world’s most economically disadvantaged communities that bear the greatest TB burden.

AlpaCure harnesses the extraordinary potential of the alpaca immune system, combining it with advanced machine learning and synthetic biology, to engineer ultrapotent antibody fragments specifically designed for next-generation diagnostic applications.

News & Publications

Nature Protocols

A robust method for kinetic binding measurement of nanobodies.

Read now
Virology

Single-domain antibodies can be used to target lentiviral vectors to SARS-CoV-2 infected cells.

Read now
New Manuscript

Describing the development of a single-domain antibody-based lateral flow assay.

Watch for updates
COVID-19 antibody testing

Drs. Tafesse and Bates worked with AHRI to develop a COVID-19 serology test which earned approval by the Ethiopian FDA.

See the story
eLife

New behavior of ESAT-6 discovered with the help of a single-domain antibody.

Read now
OBA Pitch Award

AlpaCure won the Judges' Choice and Audience's Choice awards at the 2023 Oregon Bioscience Innovation Showcase.

Check it out
iScience

Highly potent anti-spike VHH neutralizes SARS-CoV-2.

Read now
Nucleate Activator

AlpaCure won the Millipore Sigma Regional High Impact award

Check it out
Virology

HIV-specific VHH disrupts assembly of viral particles.

Read now